NICE ruling on prostate cancer drug questioned

By The Press Association2014-05-14T09:49:00

Scientists have expressed their disappointment over a preliminary decision by the National Institute of Health and Care Excellence not to offer a life-extending drug to prostate cancer patients until after they have received chemotherapy.

You need to be signed in to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All of HSJ.co.uk and our HSJ mobile app
News and insight on all areas of public funded healthcare
Expert commentary, insight and analysis from industry leaders
9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

to HSJ

Sign into your account here